Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Erleada (apalutamide) for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

Drug Name

Erleada™ / apalutamide

Developer

The Janssen Pharmaceutical Companies of Johnson & Johnson

Therapy Class

Androgen receptor inhibitor

Current Indication

Non-metastatic castration-resistant prostate cancer

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top